Drugs that contain Revefenacin

1. List of Yupelri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7585879 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7910608 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7288657 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Dec, 2025

(2 years from now)

US9765028 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US10550081 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US8541451 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7491736 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7521041 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US10106503 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US10343995 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US8053448 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US8273894 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US11247969 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US8034946 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7550595 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US11008289 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US11484531 MYLAN IRELAND LTD NA
Oct, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 9, 2023

NCE-1 date: November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

How can I launch a generic of YUPELRI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in